MCID: URN009
MIFTS: 49

Urinary System Disease

Categories: Nephrological diseases

Aliases & Classifications for Urinary System Disease

MalaCards integrated aliases for Urinary System Disease:

Name: Urinary System Disease 12 14
Congenital Malformation of the Urinary System 69
Non-Neoplastic Urinary System Disorder 69
Non-Neoplastic Urinary Tract Disease 12
Abnormality of the Urinary System 29
Urinary Tract Diseases 52
Urinary Tract Disease 12
Urinary Tract Anomaly 52
Urologic Diseases 69

Classifications:



External Ids:

Disease Ontology 12 DOID:18
NCIt 47 C27599
ICD10 33 N39 N39.8
UMLS 69 C1335051

Summaries for Urinary System Disease

Disease Ontology : 12 A disease of anatomical entity that is located in kidney, ureter, bladder and urethra.

MalaCards based summary : Urinary System Disease, also known as congenital malformation of the urinary system, is related to pyelonephritis and hypothyroidism due to iodide transport defect, and has symptoms including dysuria, polyuria and pain in urethra. An important gene associated with Urinary System Disease is B2M (Beta-2-Microglobulin), and among its related pathways/superpathways is Osteoblast Signaling. The drugs Ethanol and Heparin have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and bone, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 72 The urinary system, also known as the renal system, consists of the kidneys, ureters, bladder, and the... more...

Related Diseases for Urinary System Disease

Diseases related to Urinary System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
id Related Disease Score Top Affiliating Genes
1 pyelonephritis 30.9 ACE CRP REN
2 hypothyroidism due to iodide transport defect 11.1 ACE REN
3 atopic dermatitis 5 11.1 ALB CD79A
4 microinvasive cervical squamous cell carcinoma 11.1 ALB CD79A
5 astrocytoma 11.1 ALB B2M NAGLU
6 ovary transitional cell carcinoma 11.1 ALB CD79A
7 renal hypoplasia 11.1 NPHS1 NPHS2
8 immune-complex glomerulonephritis 11.1 ALB B2M CD79A
9 adrenal gland disease 11.1 ALB B2M CD79A
10 retinitis pigmentosa 70 11.1 ACE ALB NAGLU
11 adenocarcinoma 11.1 ACE ALB REN
12 cataract 25 11.1 ALB B2M
13 primary hyperoxaluria 11.1 ACE REN
14 autoimmune disease of cardiovascular system 11.1 ALB CD79A TLR9
15 breast mucoepidermoid carcinoma 11.1 B2M EPO PTH
16 malignant melanocytic peripheral nerve sheath tumor of mediastinum 11.1 B2M CD79A TLR9
17 clitoris cancer 11.1 ACE EPO REN
18 wernicke-korsakoff syndrome 11.1 ALB REN
19 mikulicz disease 11.1 ALB CD79A TLR9
20 membranoproliferative glomerulonephritis 11.1 ACE CD79A TLR9
21 steroid-induced glaucoma - borderline 11.0 KLK3 KRT20
22 lung lymphoma 11.0 B2M CD79A PKDREJ
23 pulpitis 11.0 ALB B2M NAGLU
24 heart sarcoma 11.0 B2M CD79A TLR9
25 pyogenic arthritis, pyoderma gangrenosum and acne 11.0 ACE EPO REN
26 46 xy gonadal dysgenesis 11.0 B2M CD79A
27 dehydration polycythemia 11.0 CD79A TLR9 TRPV1
28 plummer's disease 11.0 ALB B2M CRP
29 cryptogenic organizing pneumonia 11.0 ALB CRP TRPV1
30 allergic bronchopulmonary aspergillosis 11.0 ALB CRP KLK3
31 idiopathic juvenile osteoporosis 11.0 ALB B2M NAGLU UMOD
32 fibrosarcomatous osteosarcoma 11.0 CD79A TLR9 TRPV1
33 sarcocystosis 11.0 ALB NPHS1 NPHS2
34 pelvic varices 11.0 CD79A TLR9 TRPV1
35 opioid abuse 11.0 ALB FGF23 PTH
36 dermatomycosis 11.0 ALB CD79A CRP
37 pyrimidine metabolic disorder 11.0 ALB CD79A CRP
38 breast papillary carcinoma 11.0 ALB CRP NAGLU
39 late yaws 11.0 ALB B2M CD79A TLR9
40 medullomyoblastoma 11.0 KLK3 TLR9 TRPV1
41 spastic entropion 11.0 ALB CD79A CRP
42 thrombotic thrombocytopenic purpura 11.0 B2M PKDREJ REN UMOD
43 paranasal sinus sarcoma 11.0 ALB CD79A REN
44 astrakhan spotted fever 11.0 FGF23 PTH REN
45 early congenital syphilis 11.0 CD79A CRP TLR9
46 avoidant personality disorder 11.0 KLK3 TLR9 TRPV1
47 ischemic heart disease 11.0 ACE ALB CRP
48 hypertrophic elongation of cervix 11.0 ACE CD79A CRP
49 brain glioblastoma multiforme 11.0 CRP KLK3 TRPV1
50 cutis laxa 11.0 CD79A PTH

Graphical network of the top 20 diseases related to Urinary System Disease:



Diseases related to Urinary System Disease

Symptoms & Phenotypes for Urinary System Disease

UMLS symptoms related to Urinary System Disease:


dysuria, polyuria, pain in urethra, renal colic, urethral burning on micturition, loin pain, ureteral pain, flank tenderness, difficulty passing urine, urinary tenesmus, burning urination, uti symptoms, bladder discomfort, renal pain, other and unspecified genitourinary symptoms, urologic problem

MGI Mouse Phenotypes related to Urinary System Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 ACE ALB B2M CD79A CRP CST3
2 cardiovascular system MP:0005385 10.15 CST3 EPO FGF23 NAGLU NPHS2 PTH
3 immune system MP:0005387 10.07 ACE B2M CD79A CRP EPO FGF23
4 mortality/aging MP:0010768 9.77 ACE ALB B2M CST3 EPO FGF23
5 liver/biliary system MP:0005370 9.7 ACE ALB B2M CD79A EPO NAGLU
6 renal/urinary system MP:0005367 9.4 ALB CD79A FGF23 NAGLU NPHS1 NPHS2

Drugs & Therapeutics for Urinary System Disease

Drugs for Urinary System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1509)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
2
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 772 46507594
3
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-41-2 439260
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
5
Theophylline Approved Phase 4,Phase 2,Phase 3 58-55-9 2153
6
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1 4205-90-7 2803
7
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1 10102-43-9 145068
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
9
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
10
Ezetimibe Approved Phase 4,Phase 1 163222-33-1 150311
11
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
12
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
13
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
14
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
15
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
16
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
17
Digoxin Approved Phase 4 20830-75-5 30322 2724385
18
Colchicine Approved Phase 4,Phase 2,Phase 1 64-86-8 6167 2833
19
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
20
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-43-4 5816
21
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
22
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 59467-70-8 4192
23
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7439-89-6 23925
24
Fluvastatin Approved Phase 4,Phase 3,Phase 2 93957-54-1 1548972
25
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
26
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-31-9 3440
27
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
28
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
29
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 15307-86-5 3033
30
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 85721-33-1 2764
31
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
32
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
33
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
34
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
35
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 67-20-9 5353830
36
Prazosin Approved Phase 4,Phase 3,Phase 1,Phase 2 19216-56-9 4893
37
Nifedipine Approved Phase 4,Phase 3,Phase 2,Phase 1 21829-25-4 4485
38
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
39
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 75847-73-3 5362032 40466924
40
Ramipril Approved Phase 4,Phase 3,Phase 2 87333-19-5 5362129
41
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
42
Fosinopril Approved Phase 4,Phase 2 98048-97-6 55891
43
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Phase 1 76420-72-9 6917719
44
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 114798-26-4 3961
45
Spironolactone Approved Phase 4,Phase 2,Phase 3,Phase 1 1952-01-7, 52-01-7 5833
46
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137862-53-4 60846
47
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-93-5 3639
48
Candesartan Approved Phase 4,Phase 3,Phase 2,Phase 1 139481-59-7 2541
49
Amlodipine Approved Phase 4,Phase 3,Phase 2 88150-42-9 2162
50
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 138402-11-6 3749

Interventional clinical trials:

(show top 50) (show all 9299)

id Name Status NCT ID Phase Drugs
1 Folic Acid for Prevention of Contrast Induced Nephropathy Unknown status NCT02444013 Phase 4 Folic acid;Placebo
2 Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women Unknown status NCT00900653 Phase 4 Gynoflor E (low dose estriol with lactobacillus)
3 The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females Unknown status NCT02094703 Phase 4 Levofloxacin;Solifenacin succinate;Placebo (for Solifenacin succinate)
4 Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection Unknown status NCT00156546 Phase 4 antibiotic to reduce the recurrence of infection
5 Effects of Antibiotic Prophylaxis on Recurrent UTI in Children Unknown status NCT02357758 Phase 4 Antibiotic Prophylaxis
6 Gentamicin Bladder Instillation Trial Unknown status NCT01884467 Phase 4 Gentamicin;Placebo
7 Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Unknown status NCT01426191 Phase 4 xinzhijun
8 Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Unknown status NCT01897831 Phase 4 xin te mie
9 Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism Unknown status NCT02311010 Phase 4 Advagraf
10 Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction Unknown status NCT01871792 Phase 4 Pitavastatin;Placebo
11 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
12 Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients Unknown status NCT00999258 Phase 4 sirolimus
13 Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography Unknown status NCT00950079 Phase 4 Sodium bicarbonate;saline
14 Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
15 Safe Renal Function In Long Term Heart Transplanted Patients Unknown status NCT00505102 Phase 4 Everolimus
16 Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion Unknown status NCT00443508 Phase 4 adding Certican to therapy;reducing Tacrolimus
17 Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA) Unknown status NCT00290069 Phase 4 Tacrolimus;Rapamycin
18 A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids Unknown status NCT00273559 Phase 4 prednisone
19 Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb)/Tacrolimus/Mycophenolate in Kidney Transplantation Unknown status NCT00246129 Phase 4 Alemtuzumab;Daclizumab
20 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
21 Intravenous Iron in Patients With Anemia of Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
22 Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection Unknown status NCT01760109 Phase 4 Piperacillin Sodium and Sulbactam Sodium
23 Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis Unknown status NCT02452437 Phase 4 Oxycodone
24 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
25 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
26 Enhancing Dialysis Adequacy: Effects of Intradialytic Exercise Unknown status NCT01481688 Phase 4
27 The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease Unknown status NCT01165567 Phase 4 sarpogrelate
28 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
29 Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients Unknown status NCT00889629 Phase 4 Doxercalciferol;placebo
30 More Frequent Dialysis (>3 Treatments Per Week) Unknown status NCT00575497 Phase 4
31 Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
32 The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
33 A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children Unknown status NCT02271035 Phase 4 Deflux;Vantris
34 Efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract Unknown status NCT02366676 Phase 4 IALURIL
35 Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function Unknown status NCT01977430 Phase 4 Hydrochlorothiazide and furosemide
36 Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU Unknown status NCT01962116 Phase 4 Citrate 4%;unfractionated heparin
37 Effect of 3g Versus 2 g MMF in Combination With Tacrolimus on Progression of Renal Allograft Interstitial Fibrosis Unknown status NCT01860183 Phase 4 Mycophenolate mofetil
38 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction Unknown status NCT01788865 Phase 4
39 Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen Unknown status NCT01560572 Phase 4 tacrolimus OD, mycophenolic acid, prednisolone
40 Inspiratory Muscle Training in Patients With End Stage Renal Failure Unknown status NCT01347775 Phase 4
41 Effects of Spironolactone in Dialysis Unknown status NCT01128101 Phase 4 Spironolactone
42 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
43 Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients Unknown status NCT02590081 Phase 4 Dextrose 5%;normal saline
44 Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients Unknown status NCT01111422 Phase 4 N-acetylcysteine
45 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4 Digoxin immune fab;Placebo
46 Bladder Lavage as Decontamination Method for Asymptomatic Bacteriuria With Uropathogens in Catheterized Patients Unknown status NCT01772875 Phase 4
47 Mineralocorticoid Receptor Antagonist and Kidney Allograft Histology Unknown status NCT01510795 Phase 4 spironolactone
48 Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction Unknown status NCT01580046 Phase 4 iodixanol;iopromide
49 Hemocontrol's Effectiveness on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
50 Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation Unknown status NCT00807144 Phase 4 Tacrolimus (Kidney transplant maintenance immunosuppression);Kidney transplant maintenance immunosuppression

Search NIH Clinical Center for Urinary System Disease

Genetic Tests for Urinary System Disease

Genetic tests related to Urinary System Disease:

id Genetic test Affiliating Genes
1 Abnormality of the Urinary System 29

Anatomical Context for Urinary System Disease

MalaCards organs/tissues related to Urinary System Disease:

39
Kidney, Heart, Bone, Testes, Prostate, Liver, Endothelial

Publications for Urinary System Disease

Variations for Urinary System Disease

Expression for Urinary System Disease

Search GEO for disease gene expression data for Urinary System Disease.

Pathways for Urinary System Disease

Pathways related to Urinary System Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 9.77 FGF23 PTH

GO Terms for Urinary System Disease

Cellular components related to Urinary System Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.96 ACE ALB B2M CRP CST3 KLK3
2 extracellular region GO:0005576 9.73 ACE ALB B2M CRP CST3 EPO
3 external side of plasma membrane GO:0009897 9.62 ACE B2M CD79A TRPV1
4 extracellular space GO:0005615 9.36 ACE ALB B2M CRP CST3 EPO
5 slit diaphragm GO:0036057 9.16 NPHS1 NPHS2

Biological processes related to Urinary System Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 beta-amyloid metabolic process GO:0050435 9.32 ACE REN
2 response to molecule of bacterial origin GO:0002237 9.26 B2M TLR9
3 angiotensin maturation GO:0002003 9.16 ACE REN
4 excretion GO:0007588 9.13 NPHS1 NPHS2 UMOD
5 cellular protein metabolic process GO:0044267 9.02 ALB B2M CST3 FGF23 KLK3

Molecular functions related to Urinary System Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endopeptidase activity GO:0004175 8.8 ACE KLK3 REN

Sources for Urinary System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....